Research and development (R&D) are essential elements of Eli Lilly’s operations, enabling the company to remain at the ...

By Pranav Kashyap and Twesha Dikshit Feb 4 (Reuters) - The S&P 500 and the Dow were poised for a firmer open on Wednesday, following upbeat results from Eli Lilly and Super Micro Computer, while ...

Quick Read Healthcare Select SPDR (XLV) lagged the S&P 500 by nearly 30 percentage points over five years. Eli Lilly commands 14.45% of XLV and generated $19.29B in Q4 2025 revenue. UnitedHealth ...

Eli Lilly and Company (NYSE:LLY) is included in the list of the best performing S&P 500 stocks in the last five years. As of ...

This was the stock's second consecutive day of losses.

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Eli Lilly (LLY) achieved 54% year-over-year revenue growth to $17.6B in Q3. Tirzepatide is projected as the top-selling drug by 2030. Lilly raised its quarterly dividend 15% to $1.73 per share. The ...

Eli Lilly is riding the GLP-1 gravy train, while this competitor is struggling to get on board.